Table 1.
Transplantation demographics
| Variable | |
|---|---|
| Number of patients, no. | 816 |
| Number of centers, no. | 89 |
| Male patient gender | 470 (58) |
| Patient age, median (range), years | 37 (<1–65) |
| 0–9 years | 61 (7) |
| 10–19 years | 75 (9) |
| 20–29 years | 130 (16) |
| 30–39 years | 206 (25) |
| 40–49 years | 236 (29) |
| ≥50 years | 108 (13) |
| Donor age, median (range), years | 36 (18–59) |
| Sex of donor/patient | |
| Female/male | 144 (18) |
| Other combinations | 672 (82) |
| Karnofsky prior to transplant ≥ 90 (only evaluable for 789 patients) | 627 (79) |
| CMV serostatus of donor/patient | |
| Negative/negative | 328 (40) |
| Other combinations | 461 (56) |
| unknown | 27 (3) |
| Donor previous pregnancies (female only, n=346) | |
| 0 | 118 (34) |
| 1 | 50 (14) |
| ≥2 | 116 (34) |
| unknown | 62 (18) |
| Disease at transplant | |
| Acute myeloid leukemia | 126 (15) |
| Acute lymphoblastic leukemia | 138 (17) |
| Chronic myeloid leukemia | 390 (48) |
| Myelodysplastic syndrome | 162 (20) |
| Disease stage at transplant | |
| Early | 651 (80) |
| Intermediary | 72 (9) |
| Advanced | 85 (10) |
| Other | 8 (1) |
| Graft Type | |
| Bone marrow | 711 (87) |
| Peripheral blood stem cells | 105 (13) |
| Graft-versus-host disease prophylaxis | |
| Tacrolimus ± other | 193 (23) |
| Cyclosporine + methotrexate | 576 (71) |
| Other combinations | 47 (6) |
| Use of anti-thymocyte globulin | 75 (9) |
| Transplantation year | |
| 1988–1995 | 202 (25) |
| 1995–1999 | 324 (40) |
| 2000–2008 | 290 (36) |
Data presented as no. (%) unless otherwise specified